RollingStone Co

RollingStone Co EBIT per Share

The EBIT per Share of RollingStone Co (214610.KQ) as of Oct 21, 2026 is -1,186.10 KRW. In the previous year, EBIT per Share was -2,465.57 KRW — a change of -51.89% (higher).

EBIT per Share

-1,186.10KRW

YoY

-51.89%

Last updated:

EBIT per Share of RollingStone Co is 2025 -1,186.10 KRW. EBIT per Share of RollingStone Co was 2024 -2,465.57 KRW. It decreases by -51.89% higher compared to the previous year.

The RollingStone Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-1,017.00 KRW
Jan 1, 2019
-1,637.32 KRW
Jan 1, 2020
409.26 KRW
Jan 1, 2021
-1,300.70 KRW
Jan 1, 2022
-3,220.78 KRW
Jan 1, 2023
-2,430.35 KRW
Jan 1, 2024
-2,465.57 KRW
Jan 1, 2025
-1,186.10 KRW
The RollingStone Co EBIT per Share history
YEAREBIT per ShareYoY
-1,186.10KRW-51.89%
-2,465.57KRW+1.45%
-2,430.35KRW-24.54%
-3,220.78KRW+147.62%
-1,300.70KRW-417.82%
409.26KRW-125.00%
-1,637.32KRW+60.99%
-1,017.00KRW-31.70%
-1,489.05KRW+144.52%
-608.98KRW-90.55%
-6,446.43KRW+12.11%
-5,750.23KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RollingStone Co Stock analysis

What does RollingStone Co do? MiCo BioMed Co. Ltd. generates revenue through three business segments. The Molecular Diagnosis segment sells nucleic acid extraction equipment, gene amplification equipment, reagents, and lab chips. The Biochemical Diagnosis segment supplies complex diagnostics, anemia meters, blood glucose meters, medical devices, and strips. The Immunodiagnostic Business segment produces and sells immunodiagnostic devices and immunodiagnostic kits. These products are sold to healthcare providers and medical facilities that require diagnostic tools for patient testing and analysis. The company's products target healthcare institutions including hospitals and clinics. Medical professionals use these devices for accurate diagnosis and treatment planning. The Biochemical Diagnosis segment's blood glucose meters and anemia meters are particularly used in point-of-care testing environments. The Molecular Diagnosis segment's gene amplification equipment supports laboratory-based genetic testing procedures. MiCo BioMed's business model focuses on direct sales to medical institutions and healthcare providers. The company does not mention any third-party distributors or online sales channels. Its product portfolio serves both hospital laboratories and outpatient diagnostic centers. The Immunodiagnostic Business segment's kits are designed for rapid testing applications in clinical settings. RollingStone Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RollingStone Co stock

EBIT per Share of RollingStone Co is -1,186.10 KRW in 2025.

EBIT per Share of RollingStone Co changed from -2,465.57 KRW to -1,186.10 KRW, representing a -51.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share RollingStone Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — RollingStone Co

All Key Metrics — RollingStone Co